A narrative review of the safety concerns of deprescribing in older adults and strategies to mitigate potential harms

References

• Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370:173–184.
   PubMed Web of Science ®Google Scholar
• Garfinkel D, Ilhan B, Bahat G. Routine deprescribing of chronic medications to combat polypharmacy. Ther Adv Drug Saf. 2015;6:212–233.
   PubMedGoogle Scholar
• Reeve E, Wiese MD, Mangoni AA. Alterations in drug disposition in older adults. Expert Opin Drug Metab Toxicol. 2015;11:491–508.
   PubMed Web of Science ®Google Scholar
• Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175:827–834.
   PubMed Web of Science ®Google Scholar
• Olsson IN, Runnamo R, Engfeldt P. Medication quality and quality of life in the elderly, a cohort study. Heal Qual Life Outcomes. 2011;9:95.
   PubMed Web of Science ®Google Scholar
• Muhlack DC, Hoppe LK, Weberpals J, et al. The association of potentially inappropriate medication at older age with cardiovascular events and overall mortality: a systematic review and meta-analysis of cohort studies. J Am Med Dir Assoc. 2017;18:211–220.
   PubMed Web of Science ®Google Scholar
• Passarelli MCG, Jacob-Filho W, Figueras A. Adverse drug reactions in an elderly hospitalised population: inappropriate prescription is a leading cause. Drugs and Aging. 2005;22:767–777.
   PubMed Web of Science ®Google Scholar
• Wallace E, Mcdowell R, Bennett K, et al. Impact of potentially inappropriate prescribing on adverse drug events, health related quality of life and emergency hospital attendance in older people attending general practice: a prospective cohort study. J Gerontol A Biol Sci Med Sci. 2017;72:271–277.
   PubMed Web of Science ®Google Scholar
• Reeve E, Gnjidic D, Long J, et al. A systematic review of the emerging definition of “deprescribing” with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80:1254–1268.
   PubMed Web of Science ®Google Scholar
• Thompson W, Farrell B. Deprescribing: what is it and what does the evidence tell us? Can J Hosp Pharm. 2013;66:201.
   PubMedGoogle Scholar
• Opondo D, Eslami S, Visscher S, et al. Inappropriateness of medication prescriptions to elderly patients in the primary care setting: a systematic review. PLoS One. 2012;7:e43617.
   PubMed Web of Science ®Google Scholar
• Guaraldo L, Cano FG, Damasceno GS, et al. Inappropriate medication use among the elderly: a systematic review of administrative databases. BMC Geriatr. 2011;11:79.
   PubMed Web of Science ®Google Scholar
• Morin L, Laroche M-L, Texier G, et al. Prevalence of potentially inappropriate medication use in older adults living in nursing homes: a systematic review. J Am Med Dir Assoc. 2016;17.e1–1.e9.
   PubMed Web of Science ®Google Scholar
• Todd A, Husband A, Andrew I, et al. Inappropriate prescribing of preventative medication in patients with life-limiting illness: a systematic review. BMJ Support Palliat Care. 2016;7:113–121.
   PubMedGoogle Scholar
• Reeve E, Wiese MD. Benefits of deprescribing on patients’ adherence to medications. Int J Clin Pharm. 2014;36:26–29.
   PubMed Web of Science ®Google Scholar
• Patterson SM, Cadogan CA, Kerse N, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2014;10:CD008165.
   PubMed Web of Science ®Google Scholar
• Gnjidic D, Le Couteur DG, Kouladjian L, et al. Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med. 2012;28:237–253.
   PubMed Web of Science ®Google Scholar
• Page AT, Clifford RM, Potter K, et al. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82:583–623.
   PubMed Web of Science ®Google Scholar
• Bokhof B, Junius-Walker U. Reducing polypharmacy from the perspectives of general practitioners and older patients: a synthesis of qualitative studies. Drugs Aging. 2016;33:249–266.
   PubMed Web of Science ®Google Scholar
• Anderson K, Freeman C, Stowasser D, et al. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4:e006544.
   PubMed Web of Science ®Google Scholar
• Turner JP, Edwards S, Stanners M, et al. What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals. BMJ Open. 2016;6:e009781–2015 – 009781.
   Web of Science ®Google Scholar
• Graves T, Hanlon JT, Schmader KE, et al. Adverse events after discontinuing medications in elderly outpatients. Arch Intern Med. 1997;157:2205–2210.
   PubMedGoogle Scholar
• Bain KT, Holmes HM, Beers MH, et al. Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process. J Am Geriatr Soc. 2008;56:1946–1952.
   PubMed Web of Science ®Google Scholar
• Reeve E, Shakib S, Hendrix I, et al. The benefits and harms of deprescribing. Med J Aust. 2014;201:386–389.
   PubMed Web of Science ®Google Scholar
• Hunfeld NGM, Geus WP, Kuipers EJ. Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitors. Aliment Pharmacol Ther. 2007;25:39–46.
   PubMed Web of Science ®Google Scholar
• Lindberg G, Vieri J. Dyspepsia after withdrawal of omperazole in healthy volunteers. Gastroenterology. 2003;124:A225.
   Web of Science ®Google Scholar
• Niklasson A, Lindström L, Simrén M, et al. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol. 2010;105:1531–1537.
   PubMed Web of Science ®Google Scholar
• Qvigstad G, Waldum H. Rebound hypersecretion after inhibition of gastric acid secretion. Basic Clin Pharmacol Toxicol. 2004;94:202–208.
   PubMed Web of Science ®Google Scholar
• Gorter SL, Bijlsma JW, Cutolo M, et al. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:1010–1014.
   PubMed Web of Science ®Google Scholar
• Krasner AS. Glucocorticoid-induced adrenal insufficiency. JAMA J Am Med Assoc. 1999;282:671–676.
   PubMed Web of Science ®Google Scholar
• Margolin L, Cope DK, Bakst-Sisser R, et al. The steroid withdrawal syndrome: a review of the implications, etiology, and treatments. J Pain Symptom Manage. 2016;33:224–228.
   Google Scholar
• Potter K, Flicker L, Page A, et al. Deprescribing in frail older people: a randomised controlled trial. PLoS One. 2016;11:e0149984.
   PubMed Web of Science ®Google Scholar
• Reeve E, Thompson W, Farrell B. Deprescribing: a narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. Eur J Intern Med. 2017;38:3–11.
   PubMed Web of Science ®Google Scholar
• Gerety MB, Cornell JE, Plichta DT, et al. Adverse events related to drugs and drug withdrawal in nursing home residents. J Am Geriatr Soc. 2003;41:1326–1332.
   Google Scholar
• Marcum ZA, Pugh MJV, Amuan ME, et al. Prevalence of potentially preventable unplanned hospitalizations caused by therapeutic failures and adverse drug withdrawal events among older veterans. J Gerontol Ser A Biol Sci Med Sci. 2012;67:867–874.
   PubMed Web of Science ®Google Scholar
• Reeve E, Shakib S, Hendrix I, et al. Review of deprescribing processes and development of an evidence based, patient-centred deprescribing process. Br J Clin Pharmacol. 2014;78:738–747.
   PubMed Web of Science ®Google Scholar
• Coulson J, Routledge PA. Adverse reactions to drug withdrawal. Advers Drug React Bull. 2008;252:967–970.
   Google Scholar
• Devanand DP, Mintzer J, Schultz SK, et al. Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med. 2012;367:1497–1507.
   PubMed Web of Science ®Google Scholar
• Reeve E, Ong M, Wu A, et al. A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people. Eur J Clin Pharmacol. 2017;73:927–935.
   PubMed Web of Science ®Google Scholar
• Farrell B, Pottie K, Rojas-Fernandez CH, et al. Methodology for developing deprescribing guidelines: using evidence and GRADE to guide recommendations for deprescribing. PLoS One. 2016;11:e0161248.
   PubMed Web of Science ®Google Scholar
• Ostini R, Hegney D, Jackson C, et al. Knowing how to stop: ceasing prescribing when the medicine is no longer required. J Manag Care Pharm. 2012;18:68–72.
   PubMed Web of Science ®Google Scholar
• Paquin AM, Zimmerman K, Rudolph JL. Risk versus risk: a review of benzodiazepine reduction in older adults. Expert Opin Drug Saf. 2014;13:919–934.
   PubMed Web of Science ®Google Scholar
• Curran HV, Collins R, Fletcher S, et al. Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med. 2003;33:1223–1237.
   PubMed Web of Science ®Google Scholar
• Garfinkel D, Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010;170:1648–1654.
   PubMed Web of Science ®Google Scholar
• Garfinkel D, Zur-Gil S, Ben-Israel J. The war against polypharmacy: a new cost-effective geriatric-palliative approach for improving drug therapy in disabled elderly people. Isr Med Assoc J. 2007;9:430–434.
   PubMed Web of Science ®Google Scholar
• Iyer S, Naganathan V, McLachlan AJ, et al. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging. 2008;25:1021–1031.
   PubMed Web of Science ®Google Scholar
• Haastrup P, Paulsen MS, Begtrup LM, et al. Strategies for discontinuation of proton pump inhibitors: a systematic review. Fam Pract. 2014;31:625–630.
   PubMed Web of Science ®Google Scholar
• Boghossian TA, Rashid FJ, Thompson W, et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. Cochrane Database Syst Rev. 2017;CD011969.
   PubMed Web of Science ®Google Scholar
• Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001;121:1095–1100.
   PubMed Web of Science ®Google Scholar
• Zwisler JE, Jarbøl DE, Lassen AT, et al. Placebo-controlled discontinuation of long-term acid-suppressant therapy: a randomised trial in general practice. Int J Family Med. 2015;2015:175436.
   PubMedGoogle Scholar
• Björnsson E, Abrahamsson H, Simrén M, et al. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther. 2006;24:945–954.
   PubMed Web of Science ®Google Scholar
• George J, Kitzis I, Zandorf D, et al. Safety of nitrate withdrawal in angina-free and hemodynamically stable patients with coronary artery disease. Chest. 2003;124:1652–1657.
   PubMed Web of Science ®Google Scholar
• Azermai M, Petrovic M, Engelborghs S, et al. The effects of abrupt antipsychotic discontinuation in cognitively impaired older persons: a pilot study. Aging Ment Heal. 2012;17:125–132.
   PubMed Web of Science ®Google Scholar
• Ruths S, Straand J, Nygaard HA, et al. Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study the Bergen district nursing home study. J Am Geriatr Soc. 2004;52:1737–1743.
   PubMed Web of Science ®Google Scholar
• Ballard CG, Thomas A, Fossey J, et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry. 2004;65:114–119.
   PubMed Web of Science ®Google Scholar
• Declercq T, Petrovic M, Azermai M, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013;CD007726.
   PubMed Web of Science ®Google Scholar
• O’Regan J, Lanctôt KL, Mazereeuw G, et al. Cholinesterase inhibitor discontinuation in patients with Alzheimer’s disease: a meta-analysis of randomized controlled trials. J Clin Psychiatry. 2015;76:e1424–31.
   PubMed Web of Science ®Google Scholar
• Herrmann N, O’Regan J, Ruthirakuhan M, et al. A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease. J Am Med Dir Assoc. 2016;17:142–147.
   PubMed Web of Science ®Google Scholar
• Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol. 2001;58:427–433.
   PubMed Web of Science ®Google Scholar
• Homma A, Imai Y, Tago H, et al. Long-term safety and efficacy of donepezil in patients with severe Alzheimer’s disease: results from a 52-week, open-label, multicenter, extension study in Japan. Dement Geriatr Cogn Disord. 2009;27:232–239.
   PubMed Web of Science ®Google Scholar
• Johannsen P, Salmon E, Hampel H, et al. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer’s disease. CNS Drugs. 2006;20:311–325.
   PubMed Web of Science ®Google Scholar
• Pariente A, Fourrier-Réglat A, Bazin F, et al. Effect of treatment gaps in elderly patients with dementia treated with cholinesterase inhibitors. Neurology. 2012;78:957–963.
   PubMedGoogle Scholar
• Straand J, Fugelli PER, Laake K. Withdrawing long-term diuretic treatment among elderly patients in general practice. Fam Pract. 1993;10:38–42.
   PubMed Web of Science ®Google Scholar
• Walma EP, Hoes AW, Prins A, et al. Withdrawing long-term diuretic therapy in the elderly: a study in general practice in The Netherlands. Fam Med. 1993;25:661–664.
   PubMedGoogle Scholar
• Walma EP, Hoes AW, Van Dooren C, et al. Withdrawal of long term diuretic medication in elderly patients: a double blind randomised trial. Bmj. 1997;315:464–468.
   PubMedGoogle Scholar
• De Jonge JW, Knottnerus JA, Van Zutphen WM, et al. Short term effect of withdrawal of diuretic drugs prescribed for ankle oedema. BMJ. 1994;308:511–513.
   PubMedGoogle Scholar
• Van Der Wardt V, Harrison JK, Welsh T, et al. Withdrawal of antihypertensive medication: a systematic review. J Hypertens. 2017;35:1742–1749.
   PubMed Web of Science ®Google Scholar
• Espeland MA, Whelton PK, Kostis JB, et al. Predictors and mediators of successful long-term withdrawal from antihypertensive medications. Arch Fam Med. 1999;8:228–236.
   PubMedGoogle Scholar
• Nelson MR, Reid CM, Krum H, et al. Predictors of normotension on withdrawal of antihypertensive drugs in elderly patients: prospective study in second Australian national blood pressure study cohort. BMJ Br Med J. 2002;325:815–817.
   PubMedGoogle Scholar
• Nelson MR, Reid CM, Krum H, et al. Short-term predictors of maintenance of normotension after withdrawal of antihypertensive drugs in the Second Australian National Blood Pressure Study (ANBP2). Am J Hypertens. 2003;16:39–45.
   PubMed Web of Science ®Google Scholar
• Fotherby MD, Potter JF. Possibilities for antihypertensive drug therapy withdrawal in the elderly. J Hum Hypertens. 1994;8:857–863.
   PubMed Web of Science ®Google Scholar
• Nadal M, Wikström L, Allgulander S. Once hypertensive, always hypertensive? A three year follow-up after stopping medication. Scand J Prim Health Care. 1994;12:62–64.
   PubMedGoogle Scholar
• Kostis JB, Espeland MA, Appel L, et al. Does withdrawal of antihypertensive medication increase the risk of cardiovascular events? Am J Cardiol. 1998;82:1501–1508.
   PubMed Web of Science ®Google Scholar
• Ekbom T, Lindholm LH, Odén A, et al. A 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people. J Intern Med. 1994;235:581–588.
   PubMed Web of Science ®Google Scholar
• Fair JF. Supervised withdrawal of long-term digoxin therapy. Fam Pract. 1990;7:56–59.
   PubMed Web of Science ®Google Scholar
• Macarthur C. Withdrawal of maintenance digoxin from institutionalized elderly. Postgr Med J. 1990;66:940–942.
   PubMed Web of Science ®Google Scholar
• Sommers DK, Reitz CJ, Koch Z, et al. Digoxin withdrawal in patients with sinus rhythm. S Afr Med J. 1981;60:239–240.
   PubMedGoogle Scholar
• Hopper I, Skiba M, Von Lueder TG, et al. Digoxin withdrawal worsens clinical status in stable patients with heart failure receiving optimal contemporaneous therapy - a randomized controlled trial. J Card Fail. 2015;21:779–781.
   PubMed Web of Science ®Google Scholar
• Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:243–254.
   PubMed Web of Science ®Google Scholar
• Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment. JAMA. 2006;296:2927–2938.
   PubMed Web of Science ®Google Scholar
• Schwartz AV, Bauer DC, Cummings SR, et al. Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX Trial. J Bone Miner Res. 2010;25:976–982.
   PubMed Web of Science ®Google Scholar
• Braun KPJ, Lamberink HJ, Otte WM, et al. Antiepileptic drug withdrawal in medically and surgically treated patients: a meta-analysis of seizure recurrence and systematic review of its predictors. Epileptic Disord Epileptic Disord Epileptic Disord. 2015;17:211–228.
   PubMed Web of Science ®Google Scholar
• Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf. 2007;30:911–918.
   PubMed Web of Science ®Google Scholar
• Uijtendaal EV, Zwart-Van Rijkom JEF, Van Solinge WW, et al. Serum potassium influencing interacting drugs: risk-modifying strategies also needed at discontinuation. Ann Pharmacother. 2012;46:176–182.
   PubMed Web of Science ®Google Scholar
• Tannenbaum C, Sheehan NL. Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol. 2014;7:533–544.
   PubMed Web of Science ®Google Scholar
• Mallet L, Spinewine A, Huang A. The challenge of managing drug interactions in elderly people. Lancet. 2007;370:185–191.
   PubMed Web of Science ®Google Scholar
• Bondolfi G, Morel F, Crettol S, et al. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit. 2005;27:539–543.
   PubMed Web of Science ®Google Scholar
• Wahawisan J, Kolluru S, Nguyen T, et al. Methadone toxicity due to smoking cessation-a case report on the drug-drug interaction involving cytochrome P450 isoenzyme 1A2. Ann Pharmacother. 2011;45:34.
   PubMedGoogle Scholar
• Altaie N, Malik S, Robertson S. Theophylline toxicity - a forgotten entity. Br J Med Pr. 2011;4:a404.
   Google Scholar
• Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18:84–112.
   PubMed Web of Science ®Google Scholar
• Andersson ML, Eliasson E, Lindh JD. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. Pharmacogenomics. 2012;13:757–762.
   PubMed Web of Science ®Google Scholar
• Martinowitz U, Rabinovich J, Goldfarb D, et al. Interaction between warfarin sodium and amiodarone. N Engl J Med. 1981;304:671–672.
   PubMed Web of Science ®Google Scholar
• Bootsma JEM, Warlé-Van Herwaarden MF, Verbeek ALM, et al. Adherence to biochemical monitoring recommendations in patients starting with renin angiotensin system inhibitors. Drug Saf. 2011;34:605–614.
   PubMed Web of Science ®Google Scholar
• Lam J, Gomes T, Juurlink DN, et al. Hospitalization for hemorrhage among warfarin recipients prescribed amiodarone. Am J Cardiol. 2013;112:420–423.
   PubMed Web of Science ®Google Scholar
• Eveleigh RM, Muskens E, Van Ravesteijn H, et al. An overview of 19 instruments assessing the doctor-patient relationship: different models or concepts are used. J Clin Epidemiol. 2012;65:10–15.
   PubMed Web of Science ®Google Scholar
• Martin DJ, Garske JP, Davis MK. Relation of the therapeutic alliance with outcome and other variables: a meta-analytic review. J Consult Clin Psychol. 2000;68:438–450.
   PubMed Web of Science ®Google Scholar
• Moen J, Bohm A, Tillenius T, et al. “I don’t know how many of these [medicines] are necessary.”—a focus group study among elderly users of multiple medicines. Patient Educ Couns. 2009;74:135–141.
   PubMed Web of Science ®Google Scholar
• Alexander GC, Sayla MA, Holmes HM, et al. Prioritizing and stopping prescription medicines. Can Med Assoc J. 2006;174:1083–1084.
   Web of Science ®Google Scholar
• Sinnott C, Hugh SM, Boyce MB, et al. What to give the patient who has everything? A qualitative study of prescribing for multimorbidity in primary care. Br J Gen Pract. 2015;65:e184–91.
   PubMed Web of Science ®Google Scholar
• Schuling J, Gebben H, Veehof LJG, et al. Deprescribing medication in very elderly patients with multimorbidity: the view of Dutch GPs. A qualitative study. BMC Fam Pr. 2012;13:56.
   PubMed Web of Science ®Google Scholar
• Cantrill JA, Dowell J, Roland M. Qualitative insights into general practitioners’ views on the appropriateness of their long-term prescribing. Int J Pharm Pr. 2000;8:20–26.
   Google Scholar
• Tjia J, Givens J. Ethical framework for medication discontinuation in nursing home residents with limited life expectancy. Clin Geriatr Med. 2012;28:255–272.
   PubMed Web of Science ®Google Scholar
• Cook JM, Marshall R, Masci C, et al. Physicians’ perspectives on prescribing benzodiazepines for older adults: a qualitative study. J Gen Intern Med. 2007;22:303–307.
   PubMed Web of Science ®Google Scholar
• Reeve E, Shakib S, Hendrix I, et al. Development and validation of the patients’ attitudes towards deprescribing (PATD) questionnaire. Int J Clin Pharm. 2013;35:51–56.
   PubMed Web of Science ®Google Scholar
• Reeve E, Wiese MD, Hendrix I, et al. People’s attitudes, beliefs, and experiences regarding polypharmacy and willingness to deprescribe. J Am Geriatr Soc. 2013;61:1508–1514.
   PubMed Web of Science ®Google Scholar
• Qi K, Reeve E, Hilmer S, et al. Older peoples’ attitudes regarding polypharmacy, statin use and willingness to have statins deprescribed in Australia. Int J Clin Pharm. 2015;37:949–957.
   PubMed Web of Science ®Google Scholar
• Kalogianis MJ, Wimmer BC, Turner JP, et al. Are residents of aged care facilities willing to have their medications deprescribed? Res Soc Adm Pharm. 2016;12:784–788.
   PubMed Web of Science ®Google Scholar
• Galazzi A, Lusignani M, Chiarelli MT, et al. Attitudes towards polypharmacy and medication withdrawal among older inpatients in Italy. Int J Clin Pharm. 2016;38:454–461.
   PubMed Web of Science ®Google Scholar
• Sirois C, Ouellet N, Reeve E. Community-dwelling older people’s attitudes towards deprescribing in Canada. Res Soc Adm Pharm. 2017;13:864–870.
   PubMed Web of Science ®Google Scholar
• Ng WL, Tan MZW, Koh EYL, et al. Deprescribing: what are the views and factors influencing this concept among patients with chronic diseases in a developed Asian community? Proc Singapore Healthc. 2017;26:172–179.
   Google Scholar
• Tjia J, Kutner JS, Ritchie CS, et al. Perceptions of statin discontinuation among patients with life-limiting illness. J Palliat Med. 2017. published online 18 May.
   Web of Science ®Google Scholar
• Straand J, Sandvik H. Stopping long-term drug therapy in general practice. How well do physicians and patients agree? Fam Pract. 2001;18:597–601.
   PubMed Web of Science ®Google Scholar
• Reeve E, Low L-F, Shakib S, et al. Development and validation of the Revised Patients’ Attitudes Towards Deprescribing (rPATD) Questionnaire: versions for older adults and caregivers. Drugs Aging. 2016;33:913–928.
   PubMed Web of Science ®Google Scholar
• Linsky A, Simon SR, Stolzmann K, et al. Patient perceptions of deprescribing: survey development and psychometric assessment. Med Care. 2017;55:306–313.
   PubMed Web of Science ®Google Scholar
• Reeve E, To J, Hendrix I, et al. Patient barriers to and enablers of deprescribing: a systematic review. Drugs and Aging. 2013;30:793–807.
   PubMed Web of Science ®Google Scholar
• Reeve E, Low L-F, Hilmer SN. Beliefs and attitudes of older adults and carers about deprescribing of medications. Br J Gen Pract. 2016;66:e552–60.
   PubMed Web of Science ®Google Scholar
• Linsky A, Simon SR, Bokhour B. Patient perceptions of proactive medication discontinuation. Patient Educ Couns. 2015;98:220–225.
   PubMed Web of Science ®Google Scholar
• Luymes CH, Van der Kleij RM, Poortvliet RK, et al. Deprescribing potentially inappropriate preventive cardiovascular medication: barriers and enablers for patients and general practitioners. Ann Pharmacother. 2016;50:446–454.
   PubMed Web of Science ®Google Scholar
• Clyne B, Cooper JA, Boland F, et al. Beliefs about prescribed medication among older patients with polypharmacy: a mixed methods study in primary care. Br J Gen Pract. 2017;67:e507–18.
   PubMed Web of Science ®Google Scholar
• Todd A, Holmes H, Pearson S, et al. “I don”t think I’d be frightened if the statins went’: a phenomenological qualitative study exploring medicines use in palliative care patients, carers and healthcare professionals. BMC Palliat Care. 2016;15:13.
   PubMed Web of Science ®Google Scholar
• Griffith S. A review of the factors associated with patient compliance and the taking of prescribed medicines. Br J Gen Pract. 1990;40:114.
   PubMed Web of Science ®Google Scholar
• Page AT, Khalil H, Etherton-Beer C, et al. The efficacy of deprescribing interventions on health outcomes in people aged over 65 years: a systematic review protocol. JBI Database Syst Rev Implement Reports. 2014;12:124–134.
   Google Scholar
• Grinzi P. The inherited chronic pain patient. Aust Fam Physician. 2016;45:868–872.
   PubMed Web of Science ®Google Scholar
• Wintemute K, McDonald K, Huynh T, et al. Addressing overuse starts with physicians Choosing Wisely Canada. Can Fam Physician. 2016;62:199–200.
   PubMed Web of Science ®Google Scholar
• Cenci C. Narrative medicine and the personalisation of treatment for elderly patients. Eur J Intern Med. 2016;32:22–25.
   PubMed Web of Science ®Google Scholar
• Prazeres F, Santiago L. The knowledge, awareness, and practices of Portuguese general practitioners regarding multimorbidity and its management: qualitative perspectives from open-ended. Int J Environ Res Public Health. 2016;13:1097.
   Web of Science ®Google Scholar
• Sinnott C, Mc Hugh S, Browne J, et al. GPs’ perspectives on the management of patients with multimorbidity: systematic review and synthesis of qualitative research. BMJ Open. 2013;3:e003610.
   PubMed Web of Science ®Google Scholar
• Britten N, Stevenson FA, Barry CA, et al. Misunderstandings in prescribing decisions in general practice: qualitative study. Bmj. 2000;320:484–488.
   PubMed Web of Science ®Google Scholar
• Kutner JS, Blatchford PJ, Taylor DH, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med. 2015;175:691–700.
   PubMed Web of Science ®Google Scholar
• Gnjidic D, Le Couteur DG, Hilmer SN. Discontinuing drug treatments. Bmj. 2014;349:g7013.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine (U.S.). Committee on the assessment of the US drug safety system. The future of drug safety : promoting and protecting the health of the public/Committee on the Assessment of the US Drug Safety System, Board on Population Health and Public Health Practice.Washington, DC: The National Academies Press. 2007.
   Google Scholar
• Wahab IA, Pratt NL, Wiese MD, et al. The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. Pharmacoepidemiol Drug Saf. 2013;22:496–502.
   PubMed Web of Science ®Google Scholar
• CDC - hierarchy of controls - NIOSH workplace safety and health topic. [cited 2017 Aug 1]. Available from:: https://www.cdc.gov/niosh/topics/hierarchy/default.html.
   Google Scholar
• Politi MC. Stories of medical decision making: helping patients and clinicians manage uncertainty during clinical care. Med Decis Mak. 2015;35:NP9–10.
   PubMed Web of Science ®Google Scholar
• Politi MC, Légaré F. Physicians’ reactions to uncertainty in the context of shared decision making. Patient Educ Couns. 2010;80:155–157.
   PubMed Web of Science ®Google Scholar
• Ioannidis JPA. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294:218.
   PubMed Web of Science ®Google Scholar
• Anderson K, Foster M, Freeman C, et al. Negotiating “unmeasurable harm and benefit”. Qual Health Res. 2017. published online 12 January.
   PubMedGoogle Scholar
• Bornstein BH, Emler AC. Rationality in medical decision making: a review of the literature on doctors’ decision making biases. J Eval Clin Pract. 2001;7:97–107.
   PubMed Web of Science ®Google Scholar
• Tversky A, Kahneman D. Loss aversion in riskless choice: a reference-dependent model. Q J Econ. 1991;106:1039–1061.
   Web of Science ®Google Scholar
• Reeve E, Denig P, Hilmer SN, et al. The ethics of deprescribing in older adults. J Bioeth Inq. 2016;13:581–590.
   PubMed Web of Science ®Google Scholar